Physician profile
Robert Malacoff
NPI 1508852039
$669.00
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $58.60 · 2023: $387 · 2024: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $610.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $231.10 | 2022-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $81.07 | 2023-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $65.25 | 2023-2024 | Lifevest |
| Pfizer INC. | $55.04 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $45.62 | 2023-2024 | Inpefa |
| Astrazeneca Pharmaceuticals Lp | $37.71 | 2023-2024 | Farxiga, Brilinta |
| Merck Sharp & Dohme LLC | $34.19 | 2023-2024 | Verquvo |
| Abbott Laboratories | $24.05 | 2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Kiniksa Pharmaceuticals International, Plc | $20.52 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, Ltd. | $20.41 | 2023 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.71 | 2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $17.81 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Malacoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.